Payment overview · 2025
General Payments
$264.05
15 reported records · 10 companies
Healthcare provider profile · identity verified
Kristi A Kerner, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GREENWOOD, IN · NPI 1992787964
Verified facts
What the public records show
CMS Open Payments records show Kristi A Kerner, MD received $264.05 in general payments during 2025 across 15 reported records.
Novo Nordisk Inc accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.99 | 25.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.04 | 13.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.26 | 12.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $28.97 | 11.0% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $21.18 | 8.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.83 | 7.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.06 | 7.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.01 | 7.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.21 | 5.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4.50 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $264.05 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.02 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.71 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $28.97 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $4.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 113 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
90 | 24 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
113 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
83 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
132 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1050 | 303 |
| Levothyroxine Sodium | Levothyroxine Sodium | 797 | 195 |
| Amlodipine Besylate | Amlodipine Besylate | 601 | 164 |
| Omeprazole | Omeprazole | 564 | 156 |
| Lisinopril | Lisinopril | 546 | 147 |
| Gabapentin | Gabapentin | 364 | 111 |
| Metoprolol Succinate | Metoprolol Succinate | 351 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 327 | 95 |
| Metformin Hcl | Metformin Hcl | 326 | 100 |
| Losartan Potassium | Losartan Potassium | 325 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 276 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 261 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 224 | 55 |
| Simvastatin | Simvastatin | 223 | 65 |
| Tramadol Hcl | Tramadol Hcl | 223 | 49 |
| Montelukast Sodium | Montelukast Sodium | 218 | 66 |
| Sertraline Hcl | Sertraline Hcl | 199 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 188 | 55 |
| Furosemide | Furosemide | 185 | 49 |
| Allopurinol | Allopurinol | 174 | 46 |
| Trazodone Hcl | Trazodone Hcl | 171 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 168 | 82 |
| Escitalopram Oxalate | Escitalopram Oxalate | 163 | 52 |
| Alprazolam | Alprazolam | 160 | 42 |
| Buspirone Hcl | Buspirone Hcl | 160 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 47 |
| Glimepiride | Glimepiride | 150 | 48 |
| Potassium Chloride | Potassium Chloride | 146 | 51 |
| Alendronate Sodium | Alendronate Sodium | 145 | 50 |
| Fluoxetine Hcl | Fluoxetine Hcl | 142 | 40 |
| Meloxicam | Meloxicam | 141 | 39 |
| Ozempic | Semaglutide | 139 | 27 |
| Spironolactone | Spironolactone | 136 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 31 |
| Ezetimibe | Ezetimibe | 134 | 42 |
| Eliquis | Apixaban | 132 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 34 |
| Jardiance | Empagliflozin | 113 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 111 | 38 |
| Irbesartan | Irbesartan | 110 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 31 |
| Clonazepam | Clonazepam | 100 | 25 |
| Carvedilol | Carvedilol | 98 | 33 |
| Bupropion Xl | Bupropion Hcl | 97 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 95 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 94 | 25 |
| Valsartan | Valsartan | 91 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 25 |
| Synthroid | Levothyroxine Sodium | 90 | 24 |
| Cephalexin | Cephalexin | 89 | 67 |
| Famotidine | Famotidine | 89 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 88 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 86 | 25 |
| Pregabalin | Pregabalin | 86 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 27 |
| Amoxicillin | Amoxicillin | 79 | 72 |
| Fenofibrate | Fenofibrate | 76 | 24 |
| Donepezil Hcl | Donepezil Hcl | 75 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 74 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 73 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 73 | 17 |
| Prednisone | Prednisone | 73 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 70 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 70 | 49 |
| Lorazepam | Lorazepam | 69 | 18 |
| Atenolol | Atenolol | 68 | 22 |
| Klor-Con M20 | Potassium Chloride | 66 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 19 |
| Baclofen | Baclofen | 63 | 19 |
| Eszopiclone | Eszopiclone | 59 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 58 | 14 |
| Myrbetriq | Mirabegron | 58 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 19 |
| Mirtazapine | Mirtazapine | 55 | 15 |
| Ondansetron Odt | Ondansetron | 55 | 18 |
| Glipizide | Glipizide | 54 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 15 |
| Metformin Hcl Er | Metformin Hcl | 54 | 18 |
| Mounjaro | Tirzepatide | 53 | suppressed |
| Chlorthalidone | Chlorthalidone | 52 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 24 |
| Estradiol | Estradiol | 48 | 17 |
| Fluconazole | Fluconazole | 48 | 34 |
| Lansoprazole | Lansoprazole | 47 | 11 |
| Azithromycin | Azithromycin | 44 | 40 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 16 |
| Acyclovir | Acyclovir | 43 | 12 |
| Celecoxib | Celecoxib | 41 | 13 |
| Promethazine Hcl | Promethazine Hcl | 41 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 13 |
| Glipizide Er | Glipizide | 38 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 34 |
| Januvia | Sitagliptin Phosphate | 37 | 14 |
| Linzess | Linaclotide | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 15 |
| Meclizine Hcl | Meclizine Hcl | 33 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 32 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 12 |
| Methylprednisolone | Methylprednisolone | 31 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 22 |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | 19 |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 23 | 11 |
| Diazepam | Diazepam | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 18 |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | 11 |
| Cefuroxime | Cefuroxime Axetil | 19 | 17 |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Np Thyroid | Thyroid,pork | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 14 |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $264.05 · 15 records | Novo Nordisk Inc | ABRYSVO, Auvelity, COMIRNATY, JARDIANCE, NURTEC ODT, Ohtuvayre, Ozempic, PREVNAR 20, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error